2024 Global Tumor Markers Testing Market: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

August 2024 | - | ID: 2495AE4D232FEN
Venture Planning Group

Abstracts

Highlights%li%Identifies and evaluates major business opportunities emerging in the tumor marker marketduring the next five years%li%Examines trends in the U.S., Europe and Japan%li%Reviews current and emerging tumor markers%li%Analyzes applications of emerging diagnostic technologies%li%Forecasts sales of major tumor markers by country and market segment%li%Profiles leading market players and potential entrants %li%Suggests alternative business expansion strategies for suppliers.RationaleThe cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. ; During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.Geographic Coverage%li%France%li%Germany%li%Italy%li%Japan%li%Spain%li%UK%li%USAMarket Segmentation Analysis%li%Sales and market shares of major suppliers, by individual tumor markerand country.%li%Five-year test volume and sales forecasts for majortumor markers by country and market segment,including:%li%Hospitals%li%Commercial/Private Laboratories%li%Physician Offices/Group Practices%li%Cancer Clinics%li%Ambulatory Care Centers%li%Comprehensive market segmentation analysis, including reviewof the market dynamics, structure, size, growth and major suppliersby country.%li%Cancer statistics, etiology and recent developments in theU.S., Japan and five major European countries.Current and Emerging Products%li%Review of over 200 current and emerging tumor markers,including:%li%Biochemical Markers%li%Oncogenes%li%Growth Factors%li%Hormones%li%Colony Stimulating Factors%li%Lymphokines%li%Immunohistochemical Stains, and others.%li%Analysis of major immunoassay analyzers used fortumor marker testing, including their operating characteristics,features and selling prices.Technology Review%li%Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT,artificial intelligence, flow cytometry, biosensors, and theirpotential applications for tumor marker testing.%li%Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy.%li%Extensive listings of over 500 companies, universities andresearch centers developing new tumor markers and detection technologies.Competitive Assessments%li%Extensive strategic assessments of ; major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborativearrangements and new products in R&D.Worldwide Market Overview%li%Estimated universe of laboratories performing tumor marker testingby country.%li%Ten-year test volume and sales projections by country.Business Opportunities and Strategic Recommendations%li%Specific new product development opportunities with potentiallysignificant market appeal during the next five years.%li%Design criteria for new products.%li%Alternative market penetration strategies.%li%Potential market entry barriers and risks.MethodologyThis report is based on interviews with clinical pathologists, laboratory directors,executives from leading diagnostic companies and start-up firmsdeveloping innovative products, university scientists, as well asexperts from industry associations, venture capital firms and theinvestment banking community in the U.S., five major Europeancountries and Japan. The market projections are also based on questionnaireresponses received from hospitals, commercial/private laboratories,physician offices/group practices, cancer clinics and ambulatorycare centers in seven countries.In addition to primary sources of information, a comprehensivereview of the most recent technical and business publications, manufacturerproduct literature, patents, trade association surveys, governmentstudies, marketing and technical meeting presentations,industry analyst reports, and VPGMarketResearch's proprietary data files was conducted.Contains 1,200 pages and 450 tables

Contents

I. Introduction
II. Market Overview
III. Major Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
VI. Potential Market Entry Barriers and Risks
VII. Major Current and Emerging Cancer Diagnostic Tests

1. INTRODUCTION

2. CANCER DIAGNOSTIC CLASSIFICATION

3. ACTH

4. ALPHA-FETOPROTEIN (AFP)

5. BETA-2 MICROGLOBULIN

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. CALCITONIN

10. CARCINOEMBRIONIC ANTIGEN (CEA)

11. ESTROGEN AND PROGESTERONE RECEPTORS

12. FERRITIN

13. GASTRIN

14. HUMAN CHORIONIC GONADOTROPIN (HCG)

15. INSULIN

16. NSE

17. OCCULT BLOOD

18. PAP SMEAR/HPV

19. PROSTATIC ACID PHOSPHATASE (PAP)

20. PROSTATE-SPECIFIC ANTIGEN (PSA)

21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)

22. T AND B LYMPHOCYTES

23. TDT

24. THYROGLOBULIN

25. TISSUE POLYPEPTIDE ANTIGEN (TPA)

26. BIOCHEMICAL CANCER DIAGNOSTICS

27. ONCOGENES

- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
Table of Contents (continued)
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src and others

28. POLYPEPTIDE GROWTH FACTORS

- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha

29. ECTOPIC HORMONES

30. COLONY STIMULATING FACTORS

31. LYMPHOKINES

- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor

32. IMMUNOHISTOCHEMICAL STAINS

33. EMERGING CANCER DIAGNOSTICS

- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax